The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 11, 2019

Filed:

Jul. 24, 2017
Applicant:

Vision Global Holdings Ltd., Hong Kong, HK;

Inventors:

Bing Lou Wong, Irvine, CA (US);

Norman Fung Man Wai, Vancouver, CA;

Sui Yi Kwok, Hong Kong, HK;

Yun Chung Leung, Hong Kong, HK;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/16 (2005.12); C12N 9/78 (2005.12); C12Q 1/34 (2005.12); C07K 14/00 (2005.12); A61K 38/00 (2005.12);
U.S. Cl.
CPC ...
C12N 9/78 (2012.12); C07K 14/00 (2012.12); C12Q 1/34 (2012.12); A61K 38/00 (2012.12); C07K 2319/33 (2012.12); C07K 2319/70 (2012.12); C12Y 305/03006 (2012.12);
Abstract

The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fission protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis.


Find Patent Forward Citations

Loading…